EQT Life Sciences has closed the LSP Dementia Fund at approximately €260m, 2.6-fold over the target fund size of €100m.
Antisense drug developer Secarna Pharmaceuticals and CNS expert SciNeuro Pharmaceuticals have inked an R&D and licence option contract for CNS diseases.
The latest issue of BIOTECH Insight newsletter of Deutsche Börse in collaboration with BIOCOM AG is out, covering hot topics of the German biotech sector.
Edinburgh-based immuno-oncology expert Macomics Ltd has partnered with Ono Pharmaceutical to develop a macrophage-targeting antibody targetting cancer.
Munich-based microbiome therapeutics specialist mbiomics GmbH has raised €13m in the first closing of Series A round led by MIG Capital.
Biovian Oy’s second generation AAV platform will include Remedium Bio Inc.’s lead treatment candidate against Osteoarthritis.
How to stop hard-to-diagnose, treatment-resistant microbial pathogens was discussed by experts from 13 countries at the 7th AMR Conference in Basel.
With assets of €12m through a Series A financing, Dutch Vitestro NV aims to bring the world’s first autonomous blood drawing device to the market.
Mediar Therapeutics (Cambridge, MA, USA), a company developing a portfolio of first-in-class therapies to treat fibrosis, announces a US$105m financing including a US$85m Series A co-led by Novartis Venture Fund and Sofinnova Partners (France). The round is further joined by Pfizer Ventures, Mission BioCapital, Bristol-Myers Squibb, Eli Lilly, Ono Venture Investment, Mass General Brigham Ventures but also from more European VCs like by Gimv together with Pureos.
Danish Teitur Trophics ApS announced the completion of a €28m Series A funding to progress drugs against several neurodegenerative diseases.